Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease

Part of paid clinical trials in New Haven, Connecticut.

Sponsor
Michael J. Fox Foundation for Parkinson's Research
Study ID
NCT07020026
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
45 Years - 85 Years
Healthy Volunteers
Accepted

Interventions

  • [18F]PI-2620 — DRUG
    All participants will undergo PET imaging using the \[18F\]PI-2620 tau-binding tracer.

Study Details

The study aims to evaluate the burden of tau pathology in people with Sporadic and LRRK2 PD via in vivo imaging using the tau tracer, \[18F\]PI-2620, and a high resolution PET camera, NeuroEXPLORER.

Key Dates

Start date
May 12, 2025
Status verified
Jun 2025
Primary completion
Apr 30, 2027
Completion
Jun 30, 2027

Study Design

Enrollment
60 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: Parkinson's Disease (PD)
    Sporadic and LRRK2
  • Experimental: Tauopathy
    Progressive Supranuclear Palsy (PSP) and Corticobasal Syndrome (CBS)
  • Experimental: Healthy
    Healthy participants

Primary Outcome Measure

Comparison of tau binding between study cohort using Standardized Uptake Value ratio ( SUVr) [ Time Frame: Once during single PET imaging ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Institute for Neurodegenerative Disorders / XingImaging, LLCNew HavenConnecticut06510
Ashley Romano, Clinical Research Nurse II, RN
[email protected]
475-318-8232
Lydia Currie, Clinical Research Manager
[email protected]
475-318-8250
Neha Prakash, MBBS (PRINCIPAL_INVESTIGATOR)

Find similar trials in New Haven, CT

By condition
Parkinson's disease
By specialty
NeurologyBrain disorders
By research site
Institute for Neurodegenerative Disorders / XingImaging, LLC· New Haven, CT

Related Studies